Refractory hematologic cancer

This study tests a new drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink tumors. The…

This early-phase study tests whether adding a new drug called eganelisib to two standard AML medications (venetoclax and azacitidine) is safe for people with acute myeloid leukemia that has come back or not responded to treatment. About 48 adults will take part to find the best d…

This early-stage study tests an experimental oral drug called TQB3019 in 80 adults with advanced malignant tumors that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink tumors…

This early-stage trial tests a daily pill called APG-3288 in 180 adults with blood cancers like leukemia or lymphoma that have come back or not responded to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also look for …

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with specific types of acute leukemia that have returned or not responded to prior therapy. About 52 participants aged 12 and older will take part. The goal is to find the best dose and se…

This study tests a new immune cell treatment called AdaptNK for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially selected natural killer cells from a donor, given after chemotherapy, to help control the…

This study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with ibrutinib, in adults with relapsed or refractory primary central nervous system lymphoma (PCNSL). The trial has multiple parts to find the safest dose and see if the drug shrinks tumors. …

This study tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy can help kill cancer cells better in people with certain blood cancers that have returned or not responded to treatment. It includes adults with relapsed or refractory lymphoma, clonal cy…

This early-stage study is testing whether a drug called trichostatin A is safe for people with blood cancers that have returned or not responded to standard treatments. About 42 adults will receive the drug through an IV to find the highest safe dose and watch for side effects. T…

This early-stage trial is testing an experimental drug called ziftomenib alongside standard treatments for acute myeloid leukemia (AML) in people with specific gene mutations. About 420 participants with newly diagnosed or relapsed AML will be assigned to one of three treatment a…

This study tests a new combination of three drugs—roginolisib, venetoclax, and rituximab—in people with chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatments. The goal is to see if the combination is safe and can wipe out leukemia cells more e…

This trial tests whether giving children and teens with advanced solid tumors, brain tumors, or lymphomas drugs that match their tumor's genetic profile can help. About 90 participants will receive one of four drug combinations based on their tumor's molecular features. The goal …

This early-stage study tests an experimental drug called QLS2309 in about 186 adults with CD70-positive blood cancers that have returned or not responded to standard therapy. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Parti…

This early-phase study tests whether giving chemotherapy followed by an infusion of immune cells from a partially matched donor can help patients with relapsed or refractory leukemia get to a stem cell transplant. Only 5 participants will be enrolled to check safety and side effe…

This early-stage trial is testing a new treatment made from a person's own immune cells, called CLL-1 CAR-NK cells, for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The study aims to see if the treatment is safe and tolerable, …

This phase 2 trial is testing a combination of three drugs—venetoclax, chidamide, and azacitidine—in 30 adults with acute myeloid leukemia that has relapsed or not responded to prior treatment. The goal is to see if this combo can safely improve remission rates and survival. Part…

This study tests whether a digital health program—including a FitBit, a mobile app, and nurse coaching—can help 190 people receiving CAR-T therapy and their family caregivers better manage symptoms and distress. Participants will use the tools for 90 days while reporting their sy…

This study tests a mobile app called PACT that helps people with advanced cancer talk about and plan the care they would want if they couldn't speak for themselves. The app involves patients and their loved ones in these discussions. Researchers want to see if the app is easy to …

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This study does not test a new treatment. Instead, it follows 500 people who have already received genetically modified cell therapy for blood cancers. Researchers will check for any delayed side effects over 15 years, as required by the FDA. The goal is to understand long-term r…

This study observes older patients (60+) receiving standard CAR-T therapy for blood cancers. Researchers track how treatment affects daily activities, thinking skills, and overall quality of life. No extra treatments are given—just careful monitoring to learn more about patient e…

This study helps doctors choose the best available therapy for children and young adults with relapsed or hard-to-treat blood cancers. A team of experts reviews each patient's tumor markers and history to recommend a personalized treatment plan. The study does not give any new dr…